Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

被引：37
|
作者：
Wang, Zhan [1 ]
Chen, Juan [2 ,3 ]
Zhong, Mei-Zuo [1 ]
Huang, Juan [4 ]
Hu, Yuan-Ping [4 ]
Feng, De-Yun [5 ]
Zhou, Zhi-Jiao [6 ]
Luo, Xiao [7 ]
Liu, Zhao-Qian [2 ,3 ]
Jiang, Wu-Zhong [1 ]
Zhou, Wei-Bing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Clin Meditech Res Ctr Breast Canc, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha 410013, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Dept Pain, Changsha 410013, Hunan, Peoples R China
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 79卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ANLN; Breast cancer; Anthracycline; Prognosis; BINDING PROTEIN ANILLIN; DNA ADDUCTS; CYCLIN D1; ADJUVANT THERAPY; DOXORUBICIN; REPAIR; CYCLOPHOSPHAMIDE; EXPRESSION; RECOMBINATION; ACTIVATION;
D O I：
10.1007/s00280-017-3248-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
引用
收藏
页码：535 / 543
页数：9
相关论文
共 50 条
  • [41] Risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy and radiotherapy in young and old Asian women with breast cancer
    Lee, Chih-Hsin
    Zhang, Jun-Fu
    Yuan, Kevin Sheng-Po
    Wu, Alexander T. H.
    Wu, Szu-Yuan
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (07) : 629 - 639
  • [42] Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer
    Takala, Laura
    Barlund, Maarit
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Pirkko, Liisa
    ANTICANCER RESEARCH, 2019, 39 (01) : 279 - 283
  • [43] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy
    El-Sherbeny, Wafaa S.
    Sabry, Nesreen M.
    Sharbay, Radwa M.
    JOURNAL OF ECHOCARDIOGRAPHY, 2019, 17 (02) : 76 - 83
  • [44] Effects of the Chinese herbal medicine Hong Huang decoction, on myocardial injury in breast cancer patients who underwent anthracycline-based chemotherapy
    Cao, Sihan
    Xue, Jingxian
    Chen, Lu
    Hao, Yun
    Lu, Meijuan
    Feng, Ming
    Wang, Huanhuan
    Zhou, Jun
    Yao, Chang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [45] Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Szkandera, Joanna
    Absenger, Gudrun
    Dandachi, Nadia
    Regitnig, Peter
    Lax, Sigurd
    Stotz, Michael
    Samonigg, Hellmut
    Renner, Wilfried
    Gerger, Armin
    MOLECULAR GENETICS AND GENOMICS, 2012, 287 (09) : 755 - 764
  • [46] Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Joanna Szkandera
    Gudrun Absenger
    Nadia Dandachi
    Peter Regitnig
    Sigurd Lax
    Michael Stotz
    Hellmut Samonigg
    Wilfried Renner
    Armin Gerger
    Molecular Genetics and Genomics, 2012, 287 : 755 - 764
  • [47] Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients
    Higgins, Geoff S.
    Harris, Adrian L.
    Prevo, Remko
    Helleday, Thomas
    McKenna, W. Gillies
    Buffa, Francesca M.
    ONCOTARGET, 2010, 1 (03) : 175 - 184
  • [48] MFG-E8 overexpression is associated with poor prognosis in breast cancer patients
    Yu, Lifeng
    Zhao, Lin
    Jia, Zhen
    Bi, Jia
    Wei, Qian
    Song, Xinyue
    Jiang, Longyang
    Lin, Shu
    Wei, Minjie
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (03) : 490 - 498
  • [49] Overexpression of PBK/TOPK relates to poor prognosis of patients with breast cancer: a retrospective analysis
    Qiao, Liang
    Ba, Jinling
    Xie, Jiping
    Zhu, Ruiping
    Wan, Yi
    Zhang, Min
    Jin, Zeyu
    Guo, Zicheng
    Yu, Jiaxuan
    Chen, Sijing
    Yao, Yongqiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [50] Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy
    Martin-Richard, M
    Muñoz, M
    Albanell, J
    Colomo, L
    Bellet, M
    Rey, MJ
    Tabernero, J
    Alonso, C
    Cardesa, A
    Gascon, P
    Fernandez, PL
    ONCOLOGY, 2004, 66 (05) : 388 - 394
12345